Study to test finger cuff for heart monitoring in lung disease patients withdrawn before starting
NCT ID NCT05618093
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to see if a non-invasive finger cuff device could accurately measure how well the heart pumps blood in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). The goal was to replace the usual invasive right heart catheterization with a simpler, safer method. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Started
-
Mar 2023
- Finished
-
Feb 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient ≥ 18 years of age. * The patient must understand and sign informed consent form (ICF). * Patients with a confirmed diagnosis or suspected diagnosis of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) prior to initiation or change in therapy. * PAH or CTEPH patients undergoing right heart catheterization (RHC) as part of their standard of care. Exclusion Criteria: * BMI \< 20 or BMI \> 35. * Height less than 120 cm. * Diagnosis of atrial fibrillation, aortic or mitral valve insufficiency or stenosis, or end-stage renal disease.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic thromboembolic pulmonary hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- A 10-Question survey could give brazilian pulmonary hypertension patients a voice in their care
- Experimental blood pressure drug put to the test in healthy volunteers
- Can a new drug keep pulmonary arterial hypertension in check over the long haul?
- Could light leg workouts revive Oxygen-Starved muscles in PAH?
- Texting therapy: could a simple phone message boost exercise and quality of life in a rare lung disease?